Answers are grounded in this paper and cite their sources.
Demonstrates improved brain tumor analysis in multi-modal MRI, suggesting enhanced clinical utility.
Brain tumor diagnosis and survival prediction are among the major challenges because of high variability and the lack of precise detection and estimation. Despite prominent progress in deep learning-based brain tumor analysis, most existing approaches address segmentation, classification, and survival prediction as independent tasks, limiting their ability to exploit shared representations and reducing clinical interpretability. To address these limitations, this paper proposes 3D-UMT-Net, a multi-task framework for brain tumor segmentation, tumor classification, and patient survival prediction from multi-modal magnetic resonance imaging data. The proposed framework employs a shared encoder with task-specific decoders with additional layers, enabling effective feature sharing while preserving task-level discrimination. An improved stage-based training strategy is introduced to enhance multi-task optimization, allowing revised loss computation across different clinical tasks. Experiments are performed and evaluated on the BraTS 2020 dataset. Dice scores of 0.8657 for the mean Dice, 0.8981 for the whole tumor, 0.8733 for the tumor core, and 0.8258 for the enhancing tumor regions are achieved by the proposed method. For classification, it shows a promising accuracy of 0.9324, an area under the curve of 0.9627, and an F1-score of 0.8387. Similarly, the survival prediction task achieves a concordance index of 0.6167. These results justify that 3D-UMT-Net provides an efficient and usable multi-task solution for competitive brain tumor analysis, providing improved performance and predictions. Although the proposed framework achieved promising results on publicly available datasets, further validation using clinically acquired datasets and real-world clinical environments is necessary before assessing its clinical utility. The proposed framework is projected as a computational and strategic advancement and can be used as a base study to derive solutions for clinical decision-making only after clinical validation under institutional and medical supervision.
No takes yet. Share an insight, caveat, or question.
Uniyal et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: